567.74
+7.98(+1.43%)
Currency In USD
| Previous Close | 559.76 |
| Open | 555.97 |
| Day High | 568.13 |
| Day Low | 552.93 |
| 52-Week High | 1,211.2 |
| 52-Week Low | 476.49 |
| Volume | 844,257 |
| Average Volume | 1.3M |
| Market Cap | 60.26B |
| PE | 14.42 |
| EPS | 39.36 |
| Moving Average 50 Days | 548.16 |
| Moving Average 200 Days | 701.41 |
| Change | 7.98 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) 10 years ago, it would be worth $1,058.8 as of July 12, 2025 at a share price of $567.74. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 5 years ago, it would be worth $921.84 as of July 12, 2025 at a share price of $567.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
GlobeNewswire Inc.
Jun 26, 2025 8:05 PM GMT
TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial marke
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
GlobeNewswire Inc.
Jun 24, 2025 11:30 AM GMT
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the launch of a pi
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
GlobeNewswire Inc.
Jun 02, 2025 11:05 AM GMT
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar profile to the only FDA-approved GLP-1/GIP receptor